2, paolo marzullo , francesco barone-adesi accepted manuscript
TRANSCRIPT
Accep
ted M
anus
cript
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail:
[email protected] jc.2020-01162 See
https://academic.oup.com/endocrinesociety/pages/Author_Guidelines for Accepted
Manuscript disclaimer and additional information.
Methimazole treatment and risk of acute pancreatitis: a population-based cohort study.
Alessandro Pecere1, Marina Caputo2, Andrea Sarro1, Andrealuna Ucciero1, Angelica Zibetti1, Gianluca
Aimaretti2, Paolo Marzullo2,3, Francesco Barone-Adesi1
1 Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
2 Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara,
Italy
3 Division of General Medicine, Ospedale S. Giuseppe, I.R.C.C.S. Istituto Auxologico Italiano, Verbania
28921, Italy
Corresponding Author
Alessandro Pecere
Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
Keywords: methimazole, acute pancreatitis, hyperthyroidism, administrative database
Conflict of interest: nothing to declare
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
2
Abstract
Context: A warning has been recently issued by the European Medicine Agency (EMA)
regarding a potential increased risk of acute pancreatitis (AP) in methimazole (MMI) users.
Objective: To investigate the association between MMI and diagnosis of AP in a population-
based study.
Materials and methods: A retrospective analysis of administrative health databases was
conducted (2013-2018). Relevant data were obtained from: i) inhabitants registry, ii) hospital
discharge records (ICD-9-CM 577.0), iii) drug claims registry (ATC H03BB02). We
evaluated AP risk in MMI users in 18 months of treatment, stratifying results by trimester.
Poisson regression was used to estimate the age- and sex-adjusted Rate Ratios (RR), and the
relative 95% confidence intervals (CI), comparing rates of AP between MMI users and non-
users. The absolute risk of AP in MMI users was also calculated.
Results: A total of 23,087 new users of MMI were identified. Among them, 61
hospitalizations occurred during the study period. An increase in AP risk was evident during
the first three trimesters of therapy (RR 3.40 [95%CI 2.12-5.48]; RR 2.40 [95%CI 1.36-4.23];
RR 2.80 [95%CI 1.66-4.73]), but disappeared thereafter. The AP absolute risk in MMI users
during the first 18 months of treatment was less than 0.4% in all sex- and age-classes.
Conclusions: Our results support the EMA warning, suggesting an increased risk of AP associated
with MMI use. However, such an increase seems limited to the first months of MMI treatment.
Moreover, in absolute terms, the probability of AP is low among patients, well below 1%.
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
3
Introduction
Hyperthyroidism is an endocrine disorder associated with thyroid hormone excess,
recognized as most commonly originating from Graves’ disease, toxic multinodular goiter,
and toxic adenoma [1]. Worldwide, reported incidence is 25-93 cases per 100,000 inhabitants
[2-4]. Clinical presentation ranges from subclinical manifestations to overt thyrotoxicosis
with potential cardiovascular complications [1].
Thionamide antithyroid drugs methimazole (MMI), its prodrug carbimazole (not available in
Italy) and propylthiouracil (PTU) are the cornerstone of the therapeutic management of
hyperthyroidism [1]. MMI is recommended as the favored drug while PTU is preferred
during the first trimester of pregnancy and in patients experiencing adverse events during
MMI therapy [1]. Severe adverse events are rare and include agranulocytosis (estimated
frequency, 0.1–1.2%) and cytolytic or cholestatic hepatitis (estimated frequency, 0.1–0.2%)
[1]. In January 2019, the European Medicine Agency (EMA), basing on the available
literature and a series of EudraVigilance safety signals, issued a recommendation, adopted by
its Pharmacovigilance Risk Assessment Committee (EMA/PRAC/826440/2018), warning
against the risk of acute pancreatitis (AP) following MMI treatment based on seven case-
reports published to date [5-11]. Recently, a Danish epidemiological study [12] reported a
56% higher risk of hospitalization for AP with ongoing use of MMI, while PTU effect was
apparently null.
In view of the potential impact of these warnings on the daily endocrine management of
hyperthyroidism, we carried out a population-based cohort study to evaluate the association
between MMI treatment and AP onset.
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
4
Materials and methods
This retrospective cohort study was conducted using administrative health databases (AHDs)
of Piedmont, an Italian region with a population of around 4,400,000 inhabitants
(corresponding to 7.5% of the national Italian population). The time period encompassed in
this study was from January 1, 2013 to December 31, 2018. Data concerning only
individuals aged at least 18 years and residing in Piedmont during the aforementioned period
were considered. We used the following databases: i) inhabitants registry, containing
demographic information such as gender, birth date, death date, and other relevant
demographic information; ii) hospital information system, including hospital discharge
records (HDRs) from public and/or private hospitals; iii) drug claims registry, including
records of all outpatient drug prescriptions reimbursable by the National Health Service. As
previous studies suggest a rapid onset of AP following MMI initiation [5-11], we focused our
analysis on new users of MMI (ATC H03BB02). We used a look-back of one year to exclude
prevalent MMI users and we evaluated hospital admission rates for AP (ICD-9-CM 577.0)
during the first 18 months of treatment. In order to evaluate changes of AP risk over the
treatment course, we stratified the analysis by trimester. The general population of the region
was used as comparison group.
Multivariable Poisson regression was used to estimate Rate Ratios (RR), and their relative
95% confidence intervals (CI), adjusting the results by gender and age. We also estimated
age- and sex-specific absolute risk of AP in MMI users during the first 18 months of
treatment.
All statistical analyses were performed using Stata version 15 (StataCorp, College Station, TX).
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
5
Results
In the period 2013-2018, a total of 23,087 MMI new users were identified in the Piedmont Region.
Among them, a total of 61 hospitalizations for AP were observed during the first 18 months of
treatment, with a number of 13 hospitalization occurring in the first trimester. About 7% of the cases
with pancreatitis died during hospital stay.
The hospital admission rate for AP in MMI users during the first trimester of treatment was 270 per
100,000 person-years [95% CI 170-428], compared to a rate of 60 per 100,000 person-year [95% CI
59-61] in the general population. An increase in the risk of AP was evident during the first three
trimesters of therapy, but disappeared thereafter. RRs in the different trimesters were 3.40 [95% IC
2.12-5.48], 2.40 [95% IC 1.36-4.23], 2.80 [95% IC 1.66-4.73], 1.20 [95% IC 0.54-2.68], 1.60 [95% IC
0.80-3.21] and 0.80 [95% IC 0.30-2.14], respectively.
The absolute risk of AP in the first 18 months of treatment ranged between 0.02% and 0.39% in the
different sex- and age-classes (Table 1).
Discussion
This is a retrospective population-based study based on administrative health databases conducted
to investigate the association between MMI treatment and risk of AP in Italy.
Like radioactive iodine (RAI) and surgery, antithyroid drugs (ATDs) are approved as first-line
treatment of patients affected by Graves’ disease and as second-line therapeutic option in patients
with toxic multinodular goiter who are poor candidates for surgery and RAI, or to
ameliorate symptoms of hyperthyroidism in preparation for definitive treatments [1]. In Italy,
licensed ATDs (i.e., MMI and PTU) are the preferred primary treatment for the management of
Graves’ disease *13-15]. MMI has several advantages over PTU, such as better efficacy, less severe
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
6
side-effects, longer half-life and duration of action, and allows once-daily dosing compared with two
to three times daily dosing of PTU [1]. For this reason, a thorough knowledge of the side effects of
MMI is necessary to inform the clinical practice.
AP is increasingly considered an important and potentially fatal acute gastrointestinal condition [16].
While gallstones and alcohol consumption are recognized causes of AP, the impact of other
determinants such as specific therapeutic agents is increasingly acknowledged, and a spectrum of
drugs has been associated with AP development [17].
Currently available evidence on an increased risk of AP in patients treated with MMI is based
on seven case-reports [5-11] and one case-crossover study [12]. Four of these cases prompted
suggestive evidence of a causal relationship between AP and MMI use, as based on
recurrence after a re-challenge drug test [5, 6, 8, 9]. Conversely, two retrospective analyses
conducted in Taiwan and based on the use of the same database [18-19], failed to
demonstrate a relationship between MMI use and AP. These studies were probably hampered
by the inclusion of "ever used" MMI, which would miss cases of AP that occurred close to
MMI initiation.
In this analysis, we found that risk of AP was raised among new MMI users. The estimated
absolute risk during the first 18 months of treatment ranged between 0.02% and 0.08% in the
group of patients aged 18-59 years, while it increased to 0.16%-0.39% among patients aged
60 or more. These findings suggest that the risk of AP is increased in MMI users, but it
should be considered as a rare adverse event in the younger population, while being slightly
more frequent in the older groups. In general, data reported in a recent systematic review
contributed in demonstrating the overall safety profile of ATDs, when used in long-term
treatments as well [20].
In our analysis we also observed that the risk of AP was raised during the first three
trimesters of treatment and declined thereafter. This temporal pattern parallels that reported in
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
7
previous case reports, where the onset of AP was identified between 4 days and 12 weeks
after commencing MMI therapy with no evidence of cumulative dose-response effect [5-11].
A number of hypothetical factors could be involved in the observed association between
MMI use and AP, including reactive metabolites and intermediates formation, oxidative
stress induction, intracellular targets dysfunction and immune-mediated toxicity [21]. The
MMI reactive intermediates sulfenic and sulfinic acids are capable of interacting with
intracellular targets and are involved in liver injury [20]. Whether these metabolites play a
similar role for pancreatic injury remains to be demonstrated. Some authors previously
reported a rapid onset of AP shortly after commencing MMI treatment and AP relapse after a
second MMI challenge [5, 6, 8, 9]. This could suggest, like for liver injury, an immune-
mediated mechanism involving, through a cytokine-induced response, an immunogenic drug-
protein complex or auto-antibodies [22].
A limitation of using administrative health data is the lack of clinical information. For example, as we
did not have information on the severity of the hyperthyroidism for which therapy with MMI was
started, we were not able to directly disentangle the possible effects of the underlying condition
from that of the treatment. This could be relevant, as thyroid hormones play a pivotal role in
pancreas physiology and pathology [23], and studies in rodents found that hyperthyroidism
promotes gallstone formation in vivo, which predisposes to AP [24-25]. We note, however, that the
early onset of AP after MMI commencement and the positive re-challenge drug tests reported by
other authors suggest that most of the effect is due to the treatment. Another relevant limit in our
data is that the actual dose of the drug prescribed to patients was not collected. Hence, future
studies are warranted to evaluate whether AP following MMI treatment has specific features, or if
specific subgroups of population have an especially higher risk. In particular, it should also be
investigated whether high or low doses of MMI entail the same risk of AP.
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
8
Our results confirm and further expand previous evidence relating the use of MMI to the
development of AP, providing new insights on the risk profile of MMI users. On the other
side, the observed risk seems limited to the first three trimesters of MMI treatment. In
absolute terms, the probability of AP is low among patients, well below 1%. These aspects
should be taken into account when balancing risk and benefits of starting MMI treatment.
Thus, it could be important to resume on previous patients’ history with regards to pancreatic
health. Subsequently, particularly elderly patients should be informed on the possible risk of
acute pancreatitis during MMI treatment. Further studies are necessitated to investigate on the
individual determinants of AP risk in MMI users.
Acknowledgements
This study was partially funded by the AGING Project – Department of Excellence –
Department of Translational Medicine, Università del Piemonte Orientale and the FAR-2019
Grant issued by Università del Piemonte Orientale.
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
9
References:
1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M,
Sosa JA, Stan MN. 2016 American thyroid association guidelines for diagnosis and
management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26:
1343–1421
2. Taylor PN, Albrecht D, Scholz A, Gutierrez-buey G, Lazarus JH, Dayan CM, Okosieme OE.
Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 2018; 14:
301–316
3. Madariaga AG, Palacios SS, Guillén-grima F, Galofré JC. The incidence and prevalence of
thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 2014; 99: 923–931
4. Caputo M, Pecere A, Sarro A, Mele C, Ucciero A, Pagano L, Prodam F, Aimaretti G, Marzullo
P, Barone-Adesi F. Incidence and prevalence of hyperthyroidism: a population-based study in
the Piedmont Region, Italy. Endocrine 2020; 69: 107–112
5. Taguchi M, Yokota M, Koyano H, Endo Y, Ozawa Y. Acute pancreatitis and parotitis induced
by methimazole in a patient with Graves’ disease. Clin. Endocrinol. (Oxf). 1999; 51: 667–670
6. Yang M, Qu H, Deng H-C. Acute pancreatitis induced by methimazole in a patient with
Graves’ disease. Thyroid 2012; 22: 94–96
7. Abraham A, Raghavan P, Patel R, Rajan D, Singh J, Mustacchia P. Acute pancreatitis induced
by methimazole therapy. Case Rep. Gastroenterol. 2012; 6: 223–231
8. Jung JH, Hahm JR, Jung J, Kim SK, Kim S, Kim KY, Kim BR, Kim HJ, Jeong YY, Kim SJ. Acute
pancreatitis induced by methimazole treatment in a 51-year-old Korean man: a case report.
J. Korean Med. Sci. 2014; 29: 1170–1173
9. Agito K, Manni A. Acute pancreatitis induced by methimazole in a patient with subclinical
hyperthyroidism. J. Investig. Med. High Impact Case Reports. 2015; 1–4
10. Kikuchi I, Miyata N, Yoshimura Y, Miyamoto K, Tachikawa N. Methimazole-induced acute
pancreatitis: a case report. Clin. J. Gastroenterol. 2018; 12: 239–242
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
10
11. Su DW, Zou DJ. One case of methimazole induced pancreatitis. Chin J Clin Pract. 2008; 24:
2915
12. Brix TH, Lund LC, Henriksen DP, Folkestad L, Bonnema SJ, Hallas J, Hegedüs L. Methimazole
and risk of acute pancreatitis. Lancet Diabetes Endocrinol. 2020; 8(3): 187-189
13. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the
management of Graves’ disease. J. Clin. Endocrinol. Metab. 2012; 97: 4549–4558
14. Bartalena L. Diagnosis and management of Graves disease: A global overview. Nat. Rev.
Endocrinol. 2013; 9: 724–734
15. Negro R, Attanasio R, Grimaldi F, Guglielmi R, Papini E. A 2015 Italian survey of clinical
practice patterns in the management of Graves’ disease: comparison with European and
North American surveys. Eur. Thyroid J. 2016: 5: 112–119
16. Roberts SE, Morrison-Rees S, John A, Williams JG, Brown TH, Samuel DG. The incidence and
aetiology of acute pancreatitis across Europe. Pancreatology. 2017; 17: 155–165
17. Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis.
Curr. Gastroenterol. Rep. 2012; 14: 131–138
18. Lai S-W, Lin C-L, Liao K-F. Use of methimazole and risk of acute pancreatitis: a case-control
study in Taiwan. Indian J. Pharmacol. 2016; 48: 192–195
19. Guo J-Y, Chang C-L, Chen C-C. Association between thionamides and acute pancreatitis: a
case-control study. Thyroid. Epub 2020 May 7
20. Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review.
J. Endocrinol Invest. 2019; 42: 1273–1283.
21. Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed
mechanisms of antithyroid drugs-induced liver injury. Adv. Pharm. Bull. 2015; 5: 1–11
22. Heidari R, Ahmadi F, Rahimi HR, Azarpira N, Hosseinzadeh M, Najibi A, Niknahad H.
Exacerbated liver injury of antithyroid drugs in endotoxin-treated mice. Drug Chem. Toxicol.
2018; 3: 1–9
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
11
23. Chen C, Xie Z, Shen Y, Xia SF. The roles of thyroid and thyroid hormone in pancreas:
physiology and pathology. Int. J. Endocrinol. 2018; 1–14
24. Wang Y, Yu X, Zhao Q. zi, Zheng S, Qing W. jie, Miao C. di, Sanjay J. Thyroid dysfunction,
either hyper or hypothyroidism, promotes gallstone formation by different mechanisms. J.
Zhejiang Univ. Sci. B. 2016; 17, 515–525
25. Lerch MM, Aghdassi A. Gallstone-related pathogenesis of acute pancreatitis. Am. Pancreat.
Assoc. 2016; 1–9
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020
Accep
ted M
anus
cript
12
Table 1. Absolute risk of AP in the 18 months following MMI treatment initiation
Age (years) Men Women
18-39 0.02% 0.05%
40-59 0.09% 0.08%
60-79 0.16% 0.17%
At least 80 0.37% 0.39%
Dow
nloaded from https://academ
ic.oup.com/jcem
/advance-article/doi/10.1210/clinem/dgaa544/5894422 by C
ornell University Library user on 20 August 2020